Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (ChiCTR2600133384) titled 'Real-world Study on Perioperative Treatment of Hepatocellular Carcinoma with Camrelizumab Combined with Apatinib Mesylate' on Sept. 24.
Study Type: Observational study
Study Design:
Cohort study
Primary Sponsor: The first affiliated hospital of anhui medical university
Condition:
liver cancer
Recruitment Status: Not Recruiting
Phase: 4
Date of First Enrollment: 2026-09-24
Target Sample Size: Perioperative treatment regimen based on camrelizumab combined with apatinib mesylate:1000;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=345248
Published by H...